Combination therapy with NDV-ICOSL and anti-CTLA-4 led to regression of the majority of the virus-injected and distant tumours with long-term animal survival, which was superior to the combination of NDV-WT with anti-CTLA-4 (Fig. 4b–e). The gene discussed is ICOSLG; the disease is neoplasm.